



News Release

Suven Life sciences presenting at Neuroscience 2017 at Washington DC.

HYDERABAD, INDIA (Nov 13, 2017) – Suven Life Sciences Ltd (Suven) is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) and the status of Phase 2 clinical trial of their lead compound SUVN-502 at Neuroscience 2017, organized by Society for Neuroscience being held at Washington DC, USA during 13-15 November 2017. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro-Scientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating at this conference.

Key pharmacology, ADME, Safety and Phase-2 clinical trial status of SUVN-502 (5-HT₆ receptor antagonist), Phase 1 clinical data of SUVN-G3031 (Histamine-3 receptor antagonist) and SUVN-D4010 (5-HT₄ receptor partial agonist) along with CB2 agonist and Muscarinic (M1) acetylcholine receptor positive allosteric modulators (PAM) to treat the unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer's, Schizophrenia, ADHD; Depression & Mood Disorders and Neuropathic Pain are being presented by Suven scientists at SFN-2017. These data presentations highlight Suven's continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 1 completed SUVN-G3031 and SUVN-D4010 for Alzheimer's disease and Schizophrenia along with Phase 1 undergoing SUVN-911 for Major Depressive Disorder (MDD). In addition to that the Company has nine (9) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;